---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-052527"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-08-04T20:03:32+00:00"
generated_at: "2026-08-04T20:05:31.284502+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M

## Summary
- Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.
- EXPAREL net sales $147.8M (+3% YoY); ZILRETTA $32.6M (+4%); iovera $6.8M (+22%).
- Completed divestiture of iovera° to Zimmer Biomet for up to $140M ($70M upfront + milestones); closed July 31, 2026.
- UnitedHealthcare now provides separate reimbursement for EXPAREL, covering ~40M lives.
- Updated FY2026 total revenue guidance to $735M-$760M (from $745M-$770M) reflecting iovera divestiture.

## SEC filing metadata
- accession: 0001628280-26-052527
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-08-04T20:03:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/0001628280-26-052527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-052527
- JSON: https://secwatch.observer/filing/0001628280-26-052527.json
- Plain text: https://secwatch.observer/filing/0001628280-26-052527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.